New Employee: Lisse-Lotte Hermansson
14 Dec 2023

We are happy to announce that Lisse-Lotte Hermansson will start January 1st as the Chief Scientific Officer of Synergus RWE.

She combines a deep understanding of the use of RWE with global market access leadership in both pharma and IVD.

Lisse-Lotte holds + 20 years of successful track record in reimbursements, health economics, market access, RWD and business development in pharma and devices-diagnostics in international positions in Eli Lilly, Sanofi (Genzyme and Aventis), BMS, Astellas, Thermo FS and working in 7 countries.

Most recently member of the Advisory Board EU Digital Health Hub 2023 in Finland and a Steering Group member for PRIVASA Privacy-preserving AI for synthetic health data 2021-23. She has previously co-chaired HTA and CDx WG in EDMA/MedTech EU and has been a member of EFPIA WG for personalised medicines, HTA and orphans.

Lisse-Lotte has an M.Sc. (Econ) Helsinki School of Econ. and an M.Sc. (Health Econ.) Karolinska Ins.  Additionally, she combines her passion for understanding RWD possibilities with PhD (HE) studies at Turku University, Faculty of Medicine.

Linkedin profile